How Investors May Respond To Bristol Myers Squibb (BMY) Iberdomide Priority Review And Reblozyl Trial Progress

NodeGuardian · 2026-03-12T09:00:15+00:00

Bristol Myers Squibb's positive Phase 2 results for Reblozyl in alpha-thalassemia and FDA Priority Review for iberdomide in multiple myeloma enhance its oncology and hematology portfolio amid upcoming patent expirations, though rising leverage and past buybacks warrant investor caution.

NodeGuardian

2026-03-12 09:00:15

Abstract generation in progress

Bristol Myers Squibb recently achieved positive Phase 2 results for Reblozyl in alpha-thalassemia and secured FDA Priority Review for iberdomide in multiple myeloma. These developments are crucial as they bolster the company’s newer oncology and hematology assets, aiming to offset future patent expiries of drugs like Eliquis and Opdivo. While these successes strengthen the near-term outlook, investors should also consider the company’s rising leverage and large past buybacks.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.